Search





Search





Markets
/
Stocks
/
nasdaq-achv
/

Achieve Life Sciences Inc

ACHV

Add to Watchlist

5.290USD

-0.500-8.64%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

543.07MMarket Cap

LossP/E TTM



Achieve Life Sciences Inc

5.290

-0.500-8.64%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Achieve Life Sciences Inc

Currency: USD Updated: 2026-05-15

Key Insights

Achieve Life Sciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 84 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Achieve Life Sciences Inc's Score

Industry at a Glance

Industry Ranking

84 / 382

Overall Ranking

202 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Achieve Life Sciences Inc Highlights

StrengthsRisks

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -4.92, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 31.70M shares, increasing 14.93% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 152.46K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.82.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

13.500

Target Price

+133.16%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Achieve Life Sciences Inc is 7.02, ranking 138 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.02

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Achieve Life Sciences Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Achieve Life Sciences Inc is 6.16, ranking 311 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.92, which is -87.35% below the recent high of -0.62 and -13.23% above the recent low of -5.58.

Score

Industry at a Glance

Previous score

6.16

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 84/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Achieve Life Sciences Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 25.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

13.500

Target Price

+133.16%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Achieve Life Sciences Inc

ACHV

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Achieve Life Sciences Inc is 9.02, ranking 36 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.32 and the support level at 4.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.41

Change

-0.39

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.207

Buy

RSI(14)

60.394

Neutral

STOCH(KDJ)(9,3,3)

69.420

Sell

ATR(14)

0.387

Low Volatility

CCI(14)

55.725

Neutral

Williams %R

39.540

Buy

TRIX(12,20)

1.735

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

5.724

Sell

MA10

5.237

Buy

MA20

4.719

Buy

MA50

4.097

Buy

MA100

4.406

Buy

MA200

4.053

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Franklin Advisers, Inc.

4.37M

-2.01%

Simplify Asset Management Inc

4.97M

Contrarian Alpha Management, L.L.C.

1.67M

+8.10%

Millennium Management LLC

1.36M

+472.25%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Achieve Life Sciences Inc is 3.06, ranking 164 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.29. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.